Ostomax10 mg

Ostomax is a nitrogen-containing bisphosphonate used to slow bone loss and reduce the risk of fractures in conditions of excessive bone turnover.

Established / approved uses

• Treatment of osteoporosis in postmenopausal women, to increase bone mass and reduce the risk of hip and vertebral (spinal) fractures.
• Prevention of postmenopausal osteoporosis in women at increased risk of bone loss.
• Treatment to increase bone mass in men with osteoporosis.
• Treatment of glucocorticoid-induced osteoporosis in men and women receiving a daily dose equivalent to 7.5 mg or more of prednisone who have low bone mineral density.
• Treatment of Paget's disease of bone in patients with an elevated alkaline phosphatase, symptomatic disease, or disease that carries a risk of future complications.

Adjunct / guideline-supported use

• Ostomax is used together with adequate dietary or supplemental calcium and vitamin D as part of an overall bone-health plan; it is not a substitute for correcting calcium or vitamin D deficiency.

The optimal duration of therapy has not been definitively established for all patients (see Duration of Treatment).

Each tablet contains Alendronic acid (as alendronate sodium) as the active ingredient. Common strengths include 5 mg, 10 mg, 35 mg, 40 mg, and 70 mg, together with standard pharmaceutically inert excipients such as microcrystalline cellulose, lactose, and magnesium stearate (formulation may vary by manufacturer).

Ostomax is a synthetic, nitrogen-containing bisphosphonate that is taken by mouth. It works by binding to bone mineral and slowing the activity of the cells (osteoclasts) that break down bone, which helps preserve bone mass and reduce fracture risk over time.

Ostomax is supplied as oral tablets in several strengths, allowing once-daily or once-weekly dosing depending on the indication being treated.

Bisphosphonate (nitrogen-containing); anti-resorptive bone metabolism regulator.

Alendronic acid is a nitrogen-containing bisphosphonate. Pharmacodynamically, it binds avidly to hydroxyapatite crystals on bone surfaces undergoing active remodeling and is preferentially taken up beneath osteoclasts, the cells responsible for bone resorption. It inhibits osteoclast activity without impairing their recruitment or attachment to bone, which reduces the rate of bone turnover. Because bone formation continues while resorption is suppressed, bone mass increases progressively with continued therapy.

Pharmacokinetically, oral bioavailability is low (roughly 0.6-0.7% in fasting conditions) and is further reduced by food, beverages other than plain water, and calcium-containing products, which is why strict fasting administration is required. Absorbed drug is rapidly taken up by bone or excreted unchanged by the kidney; it is not metabolized. Once incorporated into bone matrix, Alendronic acid is pharmacologically inactive until the bone is remodeled, and it is released very slowly over months to years.

Ostomax must be taken exactly as follows to be both effective and safe:

• Take on an empty stomach, first thing in the morning, with a full glass of plain water only.
• Wait at least 30 minutes before eating, drinking anything other than plain water, or taking any other oral medicine (including calcium, antacids, and vitamins).
• Swallow the tablet whole; do not chew, crush, or suck on it.
• Remain sitting upright or standing (not reclining) for at least 30 minutes after the dose, and until after the first food of the day.

This strict technique reduces the risk of esophageal irritation and ensures adequate absorption (see Precautions and Warnings).

Calcium, antacids, and multivalent cations

Calcium supplements, antacids, and other oral products containing multivalent cations (calcium, magnesium, iron, aluminum) markedly reduce absorption of Ostomax if taken too close together. Wait at least 30 minutes after Ostomax before taking any of these.

Aspirin and NSAIDs

Aspirin-containing products taken with Ostomax doses above 10 mg daily may increase the risk of upper gastrointestinal irritation. Non-steroidal anti-inflammatory drugs (NSAIDs) may be used with caution, as both can independently irritate the stomach lining.

H2-receptor antagonists

Intravenous ranitidine has been shown to roughly double the oral bioavailability of alendronate; the clinical significance of oral H2-blockers is not established, but concurrent use should be noted by the prescriber.

Food and beverages

Coffee, tea, juice, mineral water, and food of any kind substantially reduce absorption of Ostomax and must be avoided around the time of dosing (see Administration).

The following side effects have been reported with Ostomax.

Common

• Abdominal pain, acid regurgitation, heartburn
• Nausea, dyspepsia (indigestion)
• Constipation or diarrhea
• Musculoskeletal (bone, joint, or muscle) pain
• Headache

Less common but serious — seek medical attention

Pregnancy

Data on the use of Ostomax in pregnant women are insufficient to establish safety. Bisphosphonates are incorporated into bone and released gradually over months to years, which raises a theoretical concern for fetal exposure even if the drug is stopped before conception. Ostomax should be used in women of childbearing potential or during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; use should generally be discontinued if pregnancy is recognized, and a physician should be consulted.

Lactation

It is not known whether Ostomax passes into human breast milk or affects milk production or the breastfed infant. A physician should weigh the mother's clinical need for Ostomax against the known benefits of breastfeeding and any potential risk to the infant before use during breastfeeding.

Esophageal and upper GI irritation

Ostomax can cause esophagitis, esophageal ulcers, or erosions, occasionally severe enough to require hospitalization. Strict administration technique (full glass of plain water, staying upright, waiting 30 minutes before food) is essential to reduce this risk (see Administration). Stop the medicine and seek medical advice promptly if difficulty or pain on swallowing, new or worsening heartburn, or chest pain develops.

Osteonecrosis of the jaw (ONJ)

Rare but serious jawbone damage has been reported, usually associated with tooth extraction or other invasive dental procedures, and more often in patients with cancer, chemotherapy or corticosteroid use, or poor oral hygiene. Good dental hygiene and a dental evaluation before starting long-term bisphosphonate therapy are recommended; inform the dentist that Ostomax is being taken before any invasive procedure.

Atypical femur fractures

Unusual, low-trauma fractures of the thigh bone have been reported with long-term bisphosphonate use. New or unusual thigh or groin pain during treatment should be evaluated promptly, as it may signal an incomplete fracture.

Hypocalcemia and mineral metabolism

Hypocalcemia must be corrected before starting Ostomax, and other disturbances of mineral metabolism (such as vitamin D deficiency) should be effectively treated. Adequate calcium and vitamin D intake should be maintained during treatment.

Severe musculoskeletal pain

Severe and occasionally disabling bone, joint, or muscle pain has been reported, sometimes soon after starting treatment. Discontinue and consult a physician if this occurs.

Renal impairment

Use is not recommended in patients with a creatinine clearance below 35 mL/min (see Use in Special Populations).

Duration of use

The need for continued therapy should be re-evaluated periodically, particularly after 3-5 years of use (see Duration of Treatment).

Overdose of Ostomax may cause hypocalcemia, hypophosphatemia, and upper gastrointestinal symptoms such as upset stomach, heartburn, esophagitis, gastritis, or ulcer.

If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center. While awaiting help, milk or an antacid may be given to bind the drug and reduce absorption; do not induce vomiting because of the risk of esophageal irritation, and keep the person fully upright. Dialysis is not expected to be beneficial. Do not attempt specific home treatment beyond these general first-aid measures — management should be directed by a physician.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment

No dosage adjustment is needed for a creatinine clearance of 35-60 mL/min. Ostomax is not recommended in patients with a creatinine clearance below 35 mL/min because of limited data and a theoretical risk of greater bone accumulation.

Hepatic impairment

No dosage adjustment is necessary, as Ostomax is not metabolized by the liver or excreted in bile.

Elderly patients

No overall differences in effectiveness or safety have been observed compared with younger patients, although greater sensitivity in some older individuals cannot be ruled out.

Pediatric patients

Ostomax is not indicated for use in pediatric patients; see Pediatric Uses for details.

The optimal duration of treatment with Ostomax has not been definitively established for every patient. For postmenopausal osteoporosis, some patients at low risk of fracture after 3-5 years of treatment may be considered for a temporary discontinuation ("drug holiday"), given that Ostomax remains active in bone for a prolonged period after stopping and that atypical femur fracture and osteonecrosis of the jaw risks may increase with longer duration of use. This decision should be individualized by a specialist based on fracture risk, bone density trends, and response to therapy.

For Paget's disease of bone, a defined 6-month course is typically used, with re-treatment considered only after clinical and laboratory re-evaluation.

Bisphosphonates; anti-resorptive agents; bone metabolism regulators.

Alendronic acid selectively binds to hydroxyapatite mineral on bone surfaces that are undergoing active resorption. It is taken up preferentially beneath osteoclasts, the cells that break down bone, where it inhibits their activity and reduces bone resorption without blocking the recruitment of new osteoclasts. Because bone formation by osteoblasts continues at a relatively unchanged rate while resorption slows, bone mineral density increases progressively over the course of treatment, and the resulting bone has a more normal, healthy histology than untreated osteoporotic bone.

C (FDA legacy pregnancy category system)

Ostomax is not indicated for use in pediatric patients. Safety and efficacy for the approved adult indications (postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, Paget's disease) have not been established in children.

Ostomax has been studied in a small number of children with osteogenesis imperfecta as part of clinical research; in that setting it increased spine bone mineral density but did not reduce fracture risk, and was associated with more vomiting and, in some children with fractures, delayed fracture healing compared with placebo. This is not an approved use, and Ostomax should only be given to a child under the direct supervision of a pediatric bone specialist in a research or highly specialized clinical context.